Financial Survey: Sensus Healthcare (SRTS) and Haemonetics (HAE)

Sensus Healthcare (NASDAQ:SRTS) and Haemonetics (NYSE:HAE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares Sensus Healthcare and Haemonetics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sensus Healthcare -10.21% -16.98% -11.03%
Haemonetics 2.26% 16.04% 9.36%

Analyst Recommendations

This is a summary of recent ratings for Sensus Healthcare and Haemonetics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sensus Healthcare 0 1 4 0 2.80
Haemonetics 0 1 4 0 2.80

Sensus Healthcare presently has a consensus target price of $12.25, suggesting a potential upside of 130.70%. Haemonetics has a consensus target price of $111.00, suggesting a potential upside of 4.23%. Given Sensus Healthcare’s higher probable upside, equities analysts clearly believe Sensus Healthcare is more favorable than Haemonetics.

Volatility and Risk

Sensus Healthcare has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Comparatively, Haemonetics has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500.

Earnings & Valuation

This table compares Sensus Healthcare and Haemonetics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sensus Healthcare $20.59 million 4.15 -$3.71 million ($0.28) -18.96
Haemonetics $903.92 million 6.09 $45.57 million $1.87 56.95

Haemonetics has higher revenue and earnings than Sensus Healthcare. Sensus Healthcare is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

10.1% of Sensus Healthcare shares are owned by institutional investors. Comparatively, 96.3% of Haemonetics shares are owned by institutional investors. 41.1% of Sensus Healthcare shares are owned by company insiders. Comparatively, 1.0% of Haemonetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Haemonetics beats Sensus Healthcare on 10 of the 12 factors compared between the two stocks.

About Sensus Healthcare

Sensus Healthcare, Inc. manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides Sentinel service program, which offers its customers protection for their SRT-100 and SRT-100 Vision systems. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons, eye shields, and disposable applicator tips, which are used to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was founded in 2010 and is headquartered in Boca Raton, Florida.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. The company also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, it offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, a surgical blood salvage system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; OrthoPAT, a perioperative autotranfusion system for orthopedic procedures; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply